Ranbaxy

Who makes a better suitor for Cipla and what is in it for shareholders?

Torrent Pharma and Dr Reddy’s are among the bidders. The combined India business can surpass Sun Pharma’s from any of these two deals. Investors in both Dr Reddy’s and Cipla should wait for clarity to emerge

Veterans Unpacked | D.S. Brar: "Your network is your net worth, and your credibility is your currency"

His advice to young leaders: "Focus on relationships and building trust with your customers, your partners and your employees."

SC holds Singh brothers guilty of contempt in Daiichi Sankyo case

The apex court earlier asked former Ranbaxy promoters Malvinder Singh and Shivinder Singh to give it a plan as to how they would honour the arbitral award of Rs 3,500 crore granted by a Singapore tribunal against them and in favour of Japanese drug manufacturer Daiichi Sankyo.

Delhi Police arrests former Ranbaxy promoter Shivinder Singh

The EOW of Delhi Police is also on the lookout for former Ranbaxy CEO Malvinder Singh.

Policy| Bottle of Lies: What ails India’s drug industry

Like other books on corporate fraud, Bottle of Lies is a cautionary tale about how the relentless quest for high growth and profits at any costs can corrupt organisations in the absence of a strong, ethical core and sustained, rigorous, regulatory oversight.

SC asks ex-Ranbaxy promoters to apprise how they'll comply with Rs 3500 crore arbitral award

A bench headed by Chief Justice Ranjan Googi asked the Singh brothers, who were present in the court, to consult their financial and legal advisors and give a concrete plan on how they will comply with the tribunal's order.

Opinion | Sun Pharma: New governance structure needed to protect investors' interest

The whistleblower allegations have raised governance concerns at Sun Pharma. Investors are better placed in proactively raising their concerns with the board, to ensure that the new governance structure at Sun Pharma is robust, in their compliance and intent

NCLT dismisses HDFC plea for initiating insolvency proceedings against RHC Holding

The Delhi High Court has already granted a status quo over sale of assets by RHC Holding.

A message for Indian pharma: Do what you say, say what you do

Over the last decade, “data integrity” has turned out to be the most discussed and perhaps the most dreaded word for the Indian pharmaceutical companies.

Analysts retain buy on Sun Pharma as USFDA clears Mohali, Halol unit resolution key

CLSA says Mohali plant clearance is a significant positive development for the company and shows progress on regulatory issues. Clearance makes a large oral solid dosage site available to de-risk existing sites.

USFDA lifts import ban on Sun Pharma's Mohali plant, shares surge 5%

Sun Pharma said the proposed action will clear path for supply approved products from the Mohali faciity to the US market.

Sun Pharma soars 6% on US FDA’s plan to lift import alert at Mohali

The company informed the exchanges that the US Food and Drug Administration was planning to remove the firm from Official Action Initiated (OIA) status.

Trump policies stressful for India pharma cos: Ex-Ranbaxy CEO

Former CEO of Ranbaxy, Brian Tempest, expects more pricing pressure to come in US under Donald Trump administration.

Daiichi to shut down Indian R&D centre; 170 employees impacted

â€œDaiichi Sankyo is reviewing its global R&D system with the aim of decreasing R&D operations costs and redistributing resources to the further development of its R&D pipeline,â€ the company said in a statement.

Nifty on Cloud Nine! 9 stocks with a high margin of safety

With Nifty a whisker away from its lifetime high and valuation touching 21X FY17P and 18X FY18P earnings, the Street looks cautious. Is it time to take money off the table?

COMMENT: Is Sun Pharma suffering on account of unrelated diversification?

For investors, the Sun Pharma stock has long stood for a focus on growth, both through organic and inorganic routes. Is this lack of focus through unrelated investments the reason for its underperformance?

Sun Pharma, Wockhardt in news on re-inspections, lawsuits

Wockhardt, Sun Pharma, Tara, Novartis and other pharma company Perrigo are also in focus on account of reports from the US that there are lawsuits filed by Unions representing the New York Police Department on price collusion of two dermatology products.

Positive on ITC & ICICI Bank, says Deven Choksey

In an interview to CNBC-TV18, Deven Choksey, MD of KRChoksey Investment Managers Private Limited shared his readings and outlook on specific stocks and sectors.

Look at Sun Pharma, says Gaurang Shah

Gaurang Shah of Geojit BNP Paribas is of the view that one may look at Sun Pharmaceutical Industries.

Making Ranbaxy units cGMP compliant time consuming: Sun Pharma

Sun Pharma sees remediation process at erstwhile Ranbaxy facilities as a "time consuming" process even as it aims to bring at least one of the plants to conform to current good manufacturing practice regulations (cGMP) in the current fiscal.

Continue to remain opportunistic for acquisitions: Sun Pharma

The merger between Sun and Ranbaxy achieved closure towards the end of March 2015.

Sun Pharma falls 6% on weak sales guidance, price pressure woes

The company also said that the pharma major will continue to build speciality business which could impact short term profitability. It also cautioned that it could lose anywhere between 5-10 percent due to pricing pressure and peer consolidation in the US.